TELO
Telomir Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.04
−0.95%Oct 6, 2026, 12:03 UTC
Telomir Pharmaceuticals, Inc. agreed to issue and sell 4,843,300 shares of common stock in a private placement at $1.16 per share for gross proceeds of approximately $5.6 million.
Source:Oct 6, 2026, 12:00 UTC
Billionaire entrepreneur and existing significant shareholder John Paul DeJoria increased his investment in Telomir Pharmaceuticals by an additional $1.0 million as part of the company's PIPE financing.
Source:Sep 14, 2026, 12:00 UTC
Telomir Pharmaceuticals announced research findings from The Ohio State University College of Veterinary Medicine showing that Telomir-Zn inhibits cell growth in human and canine osteosarcoma models.
Source: